ClinicalTrials.gg
Active, not recruitingNCT06964191Updated Jul 8, 2026

Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension

A Phase 2 interventional study of PA5108 Ocular Implant low dose and PA5108 Ocular Implant, high dose in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by PolyActiva Pty Ltd. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by PolyActiva Pty Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Planned enrollment
153rd of 279
75 · median 84
Started
2025
with 22 others
Phase 2
76 of 348
5 open now
Primary completion
2026-11
later than 23 of 66 live
Registered
317th of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 153rd largest by planned enrollment of the 279 interventional ones that give a count, is one of 23 that started in 2025, is one of 76 in phase 2, reaches primary completion later than 23 of the 66 other live ones, and was the 317th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to the standard treatment therapy.

Read the detailed description

This is a randomised, parallel, masked, active-controlled study that will evaluate the efficacy and safety of a low dose and a high dose of PA5108 Ocular Implant with single redosing during the study, in adults with open-angle glaucoma or ocular hypertension.

The study will also collect information on the implant administration procedure and overall experience from study participants.

The study plans to recruit approximately 75 participants.

Eligible participants will be randomly selected to receive one of the following treatments:

  • PA5108 Ocular Implant - low dose in the study eye, and Latanoprost 0.005% eye drops in the other eye
  • PA5108 Ocular Implant - high dose in the study eye, and Latanoprost 0.005% eye drops in the other eye
  • Latanoprost 0.005% eye drops in both eyes (control treatment group) If allocated to receive either of the ocular implants, a second implant of the same dose will be administered at 26 weeks and participants will be followed for safety and intraocular pressure control until week 58 or until the implant is no longer visible in the study eye.
03

Conditions studied

  • Glaucoma, Open-Angle
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ability to provide and follow study instructions
  • 18 years of age or older
  • Diagnosis of open-angle glaucoma or ocular hypertension in both eyes
  • Qualifying IOPs across 2 visits following washout of IOP-lowering medication, if applicable
  • Qualifying best-corrected visual acuity BCVA using Early Treatment Diabetic Retinopathy Study (ETDRS) chart in study eye
  • Qualifying corneal endothelial cell density (CEDC) in the study eye

Key Exclusion Criteria:

  • Pseudoexfoliation or pigment dispersion, narrow irido-corneal drainage angles, or existing peripheral anterior synechiae in the inferior angle either eye.
  • Advanced or severe glaucoma
  • Disqualifying central corneal thickness in either eye
  • Significant other ocular conditions that could prevent accurate assessment of IOP and corneal health
  • Uncontrolled medical conditions
  • Have previously received, any injectable glaucoma medication into the anterior chamber of the study eye
  • Have received intravitreal injections in the study eye within the last 3 months of the Screening Visit and anticipated need for an intravitreal injection during the course of the study
  • Unwilling or unable to discontinue, in either eye, soft contact lens wear at least 2 days and hard contact lens wear 1 week before scheduled study visits and on implant administration days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    PA5108 Ocular Implant low dose

    PA5108 Ocular Implant, low dose in the study eye, and latanoprost ophthalmic solution 0.005% once daily pm in the other eye.

    Combination Product: PA5108 Ocular Implant low dose · Drug: Latanoprost 0.005% Ophthalmic Solution

  • Experimental
    PA5108 Ocular Implant high dose

    PA5108 Ocular Implant, high dose in the study eye, and latanoprost ophthalmic solution 0.005% once daily pm in the other eye.

    Combination Product: PA5108 Ocular Implant, high dose · Drug: Latanoprost 0.005% Ophthalmic Solution

  • Active comparator
    Latanoprost ophthalmic solution 0.005%

    Latanoprost ophthalmic solution 0.005% once daily pm in both eyes.

    Drug: Latanoprost 0.005% Ophthalmic Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy: change in mean diurnal intraocular pressure in study eye

    Time frame: From Baseline to 12 weeks

  2. Incidence of ocular symptoms and ocular treatment-emergent adverse events.

    Ocular safety and tolerability (AEs)

    Time frame: Day 1 to study completion until at least Week 58

  3. Clinically significant change on slit-lamp exam

    Slit-lamp biomicroscopy of eye to observe clinically significant changes.

    Time frame: Day 1 to study completion until at least Week 58

  4. Clinically significant change in corneal endothelial cells

    Corneal endothelial cell density (cells/mm2) measured by specular microscopy.

    Time frame: Day 1 to study completion until at least Week 58

Secondary outcomes

  1. Efficacy: intraocular pressure change from baseline in study eye at different diurnal time points.

    Time frame: Weeks 2-52

Other outcomes

  1. Exploratory: Gather data on implant administration procedure and overall experience from study participants.

    A questionnaire comprising two questions will be used at Week 24 and Week 58 to assess the administration procedure.

    Time frame: At 24 and 58 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2026, 17 months after the start.

Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's planned 17 months is above that.

Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
May 9, 2025
StartActual
May 31, 2025
Primary completionEst.
Nov 15, 2026
CompletionEst.
Nov 15, 2026
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06964191
Lead sponsor
PolyActiva Pty Ltd
Collaborators
IUVO S.r.l.
Responsible party
Sponsor
First posted
May 9, 2025
Start date
May 31, 2025
Primary completion
Nov 15, 2026 (estimated)
Completion
Nov 15, 2026 (estimated)
Last update
Jul 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PA5108

Start the discussion